



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/647,766 Confirmation No.: 2747  
Applicant: Somers  
Filed: August 25, 2003  
TC/AU.: Unassigned  
Examiner: Unassigned  
Docket No.: 04676.105082 ATH 109 CON 6  
Customer No.: 20786  
Title: Compounds and Methods for the Inhibition of the Expression of VCAM-1  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**Transmittal of Information Disclosure Statement**

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of the following references are enclosed: AM, AN, AO, AP, AR, AV, AW, AY, AZ, AAC, BH, BK, BL, BM, BN, BO, BP, BQ, BR, BU, BZ, CB, CP, DB, DC, DD, DE, DG, DH, DJ, DK, DL, DM, EF, FM, FN, GA, GC, and GD. All other listed references were cited during prosecution of the parent applications U.S.S.N. 09/079,213, now issued as USP 6,147,250, and U.S.S.N. 09/370,046, now issued as USP 6,548,699. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe any fees are due because this paper is submitted before the mailing of a first Office Action on the merits of the application, as under 37 C.F.R. §1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

Madeline I. Johnston  
Reg. No. 36,174

Dated August 31, 2004  
King & Spalding, LLP  
191 Peachtree Street, N.E., Atlanta, GA 30303  
Office: (404)572-4600/ Fax: 404-572-5145

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 31, 2004.

Jennifer A. Williams



Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

7

Complete if Known

Application Number	10/647,766
Filing Date	August 25, 2003
First Named Inventor	Somers
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	04676.105082 ATH 109 CON 6

3563879\_2.DOC

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
	AA	3,179,701	A	Rocklin	04-20-1965	
	AB	3,479,407	A	Laufer	11-18-1969	
	AC	3,576,883	A	Neuwirth	04-27-1971	
	AD	3,952,064	A	Whalley	04-20-1976	
	AE	4,029,812	A	Wagner	06-14-1977	
	AF	4,076,841	A	Wagner	02-28-1978	
	AG	4,078,084	A	Wagner	03-07-1978	
	AH	4,115,590	A	Lerner	09-19-1978	
	AI	4,752,616	A	Hall	06-21-1988	
	AJ	4,755,524	A	Mueller <i>et al.</i>	07-05-1988	
	AK	4,954,514	A	Kita	09-04-1990	
	AL	4,968,710	A	Rustad	11-06-1990	
	AM	4,975,467	A	Ku <i>et al.</i>	12-04-1990	
	AN	5,043,330	A	Nguyen <i>et al.</i>	08-27-1991	
	AO	5,061,734	A	Mao <i>et al.</i>	10-29-1991	
	AP	5,066,822	A	Rustad <i>et al.</i>	11-19-1991	
	AQ	5,084,214	A	Kita <i>et al.</i>	01-28-1992	
	AR	5,112,870	A	Mao <i>et al.</i>	05-12-1992	
	AS	5,155,250	A	Parker	10-13-1992	
	AT	5,206,247	A	Regnier	04-27-1993	
	AU	5,262,439	A	Parthasarathy	11-16-1993	
	AV	5,294,724	A	Jendralla <i>et al.</i>	03-15-1994	
	AW	5,310,949	A	Dufresne <i>et al.</i>	05-10-1994	
	AX	5,380,747	A	Medford	01-10-1995	
	AY	5,411,741	A	Azias	05-02-1995	
	AZ	5,512,595	A	Regnier <i>et al.</i>	04-30-1996	
	AAA	5,608,095	A	Parker	03-04-1997	
	AAB	5,627,205	A	Regnier <i>et al.</i>	05-06-1997	
	AAC	5,693,337	A	Suzuki <i>et al.</i>	12-02-1997	
	AAD	5,739,374	A	Janssen <i>et al.</i>	04-14-1998	
	AAE	5,750,351	A	Medford	05-12-1998	
	AAF	5,773,209	A	Medford <i>et al.</i>	06-30-1998	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

7

Complete if Known

Application Number	10/647,766
Filing Date	August 25, 2003
First Named Inventor	Somers
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	04676.105082 ATH 109 CON 6

3563879 2.DOC

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
	BA	5,773,231	A	Medford <i>et al.</i>	06-30-1998	
	BB	5,783,596	A	Medford <i>et al.</i>	07-21-1998	
	BC	5,792,787	A	Medford <i>et al.</i>	08-11-1998	
	BD	5,807,884	A	Medford <i>et al.</i>	09-15-1998	
	BE	5,811,449	A	Medford <i>et al.</i>	09-22-1998	
	BF	5,821,260	A	Medford <i>et al.</i>	10-13-1998	
	BG	5,846,959	A	Medford <i>et al.</i>	12-08-1998	
	BH	6,037,377	A	Anderskewitz <i>et al.</i>	03-14-2000	
	BI	6,121,319	A	Somers	09-19-2000	
	BJ	6,147,250	A	Somers	11-14-2000	
	BK	6,323,359	B1	Jass	11-27-2001	
	BL	2002-0188118	A1	Meng	12-12-2002	
	BM	2002-0193446	A1	Meng	12-19-2002	
	BN	2003-0064967	A1	Luchoomun <i>et al.</i>	04-03-2003	
	BO	6,548,699	B1	Somers	04-15-2003	
	BP	6,602,914	B2	Meng	08-05-2003	
	BQ	6,617,352	B2	Somers	09-09-2003	
	BR	6,670,398	B2	Edwards <i>et al.</i>	12-30-2003	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	BS	DE	27 16 125	A1	Yoshitomo Pharm. Inds. Ltd.	10-27-1977		
	BT	EP	0,190,682		G.D. Searle & Co.	08-13-1986		
	BU	EP	0,254,272	A2	Merrell Dow Pharmaceuticals Inc.	01-27-1988		
	BV	EP	0,292,660	A2	Merrell Dow Pharmaceuticals Inc.	11-30-1988		
	BW	EP	0,317,165	B1	Riker Laboratories Inc.	05-24-1989		
	BX	EP	0,348,203	A1	Shionogi Seiyaku KK	12-27-1989		
	BY	EP	0,405,788	A2	Shionogi Seiyaku KK	01-02-1991		
	BZ	EP	0,418,648	A1	Hoechst AG.	03-27-1991		
	BAA	EP	0,621,255	A1	Adir et Co.	10-26-1994		

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

7

Complete if Known

Application Number	10/647,766
Filing Date	August 25, 2003
First Named Inventor	Somers
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	04676.105082 ATH 109 CON 6

3563879 2.DOC

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number				
CA	EP	0,763,527	A1	Adir et Co.	03-19-1997		
CB	EP	0,866,049	A2	Univesity of Wales (Swansea)	09-23-1998		
CC	FR	2,130,975	A5	Robert Aries	11-10-1972		
CD	FR	2,133,024	A5	Robert Aries	11-24-1972		
CE	FR	2,134,810	A5	Robert Aries	12-08-1972		
CF	FR	2,140,769	A5	Robert Aries	01-19-1973		
CG	FR	2,140,771	A5	Robert Aries	01-19-1973		
CH	FR	2,168,137	A1	Dynachim	08-31-1973		
CI	GB	1,136,539		Uniroyal Inc.	12-11-1968		
CJ	GB	1,148,550		Uniroyal Inc.	04-16-1969		
CK	GB	1,199,871	A	Consolidation Coal Co.	07-22-1970		
CL	JP	49-075552 [74-75,552]	A	Sagami Chem. Res. Ctr., [Fujisawa], <i>Chem. Abs.</i> , AN 82(13):86196 (March 31, 1975), XP002115592	07-20-1974		
CM	JP	06-312978 [94-212978]	A	Nippon Tobacco Sangyo <i>et al.</i> [Kobayashi], <i>Chem. Abs.</i> , AN 122(15): 187387 (April 10, 1995) XP002115602	11-08-1994		
CN	JP	09-059258 [97-059258]	A	Ono Pharm. Co., [Toshiaki], <i>Chem. Abs.</i> , AN 126:277465 (May 26, 1997), XP002115599 and XP002115593	03-04-1997		
CO	JP	73-28425			12-19-1995		
CP	WO	93/02051	A2	Pfizer	02-04-1993		
CQ	WO	94/07869	A1	Zeneca; British Technology Grp.	04-14-1994		
CR	WO	95/09158	A1	Zeneca; British Technology Grp.	04-06-1995		
CS	WO	95/15760	A1	Merrell Dow Pharmaceuticals	06-15-1995		
CT	WO	95/17408	A1	Glaxo Wellcome	06-29-1995		
CU	WO	95/30415	A1	Emory University	11-16-1995		
CV	WO	96/12703	A1	G.D. Searle & Co.	05-02-1996		
CW	WO	97/15546	A1	Nippon Shinyaku Co. Ltd.	05-01-1997		
CX	WO	97/26258	A1	Janssen Pharaceutica N.V.	07-24-1997		
CY	WO	97/48694	A1	University of Texas	12-24-1997		
CZ	WO	98/22418	A1	Hoechst Marion Roussel Inc.	05-28-1998		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

7

*Complete if Known*

Application Number	10/647,766
Filing Date	August 25, 2003
First Named Inventor	Somers
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	04676.105082 ATH 109 CON 6

3563879\_2.DOC

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
DA	WO	98/51289	A2		Atherogenics	11-19-1998		
DB	WO	98/51662	A2		Atherogenics Inc.	11-19-1998		
DC	WO	99/15159	A2		Nova Molecular Inc.	04-01-1999		
DD	WO	99/24400	A1		Vyrex	05-20-1998		
DE	WO	00/26167	A1		Galderma Res. & Dev. S.N.C.	05-11-2000		
DF	WO	00/26184	A1		Nemotel; Dr. Rudolph Eidenschink	05-11-2000		
DG	WO	00/28332	A1		Atherogenics	05-18-2000		
DH	WO	00/31053	A1		Janssen Pharmaceutica N.V.	06-02-2000		
DI	WO	00/59509	A1		Novartis (CH); Novartis (AT)	10-12-2000		
DJ	WO	01/70757	A2,3		Atherogenics	09-27-2001		
DK	WO	01/79164	A2,3		Atherogenics	10-25-2001		

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
DL		ANONYMOUS, "AtheroGenics announces positive Phase II results from CART-1 CLINICAL TRIAL for restenosis," (Press Release November 12, 2001).	
DM		ANONYMOUS, "AtheroGenics: Faster than anticipated," <i>BioCentury Extra (The Bernstein Report of Biobusiness)</i> , Reprint from May 29, 2001.	
DN		BARNHART, J.W., <i>et al.</i> , "Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs, <i>Pharmacochem. Libr.</i> , 1991(17):277-299 (1991). XP002095165	
DO		BARON, J.L., <i>et al.</i> , "The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between $\alpha$ -4-integrins and vascular cell adhesion molecule-1", <i>J. Clin. Invest.</i> 93:1700-1708 (April 1994).	
DP		BROWN, <i>et al.</i> , "Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis", <i>Ann. Rev. Biochem.</i> , 52:223-261 (1983).	
DQ		BURKLY, L.C., <i>et al.</i> , "Protection against adoptive transfer of autoimmune diabetes mediated through very late antigen-4 integrin", <i>Diabetes</i> , 43:529-534 (April 1994).	
DR		CAREW, <i>et al.</i> , "Antiatherogenic effect of probucol unrelated to its hypcholesterolemic effect: Evidence that antioxidants <i>in vivo</i> can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:7725-7729 (November 1987).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	5	of	7	Attorney Docket Number	04676.105082 ATH 109 CON 6
-------	---	----	---	------------------------	----------------------------

3563879 2.DOC

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	EA	COMINACINI, L., <i>et al.</i> , <i>Free Radical Biology and Medicine</i> , 22(1/2):117-127 (1996) XP002095164.	
	EB	De MEGLIO, P., "New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity," <i>Il Farmaco, Ed. Sci.</i> 40(11):833-844 (1985). <i>With partial translation. Chem. Abstracts</i> , 104(5):28675, (February 3, 1986), XP 002124424.	y
	EC	FELDMAN, D., <i>et al.</i> , "The In Vitro and Ex Vivo Antioxidant Properties, and Hypolipidemic Activity of CGP 2881," <i>Atherosclerosis</i> , 144:343-355 (December 28, 1998)	
	ED	FOLKMAN, J., <i>et al.</i> , "Angiogenesis", <i>J. Biol. Chem.</i> , 267(16):10931-10934 (June 5, 1992).	
	EE	FRUEBIS, J., "A Comparison of the Antiatherogenic Effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits," <i>The American Society for Clinical Investigation, Inc.</i> , 94:392-398 (July 1994).	
	EF	GERSHBEIN <i>et al.</i> , "Action of drugs and chemical agents on rat liver regeneration," <i>Drug and Chemical Toxicology</i> , 8(3):125-143 (1985).	
	EG	HEEG, <i>et al.</i> , "Plasma levels of Probucol in man after single and repeated oral doses", <i>La Nouvelle Presse Medicale</i> , 9(40):2990-2994 (October 30, 1980). <i>Abstract in English.</i>	
	EH	IADEMARCO, M.F., <i>et al.</i> , "Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1)", <i>J. Biol. Chem.</i> 267(23):16323-16329 (August 15, 1992).	
	EI	KAZUYA <i>et al.</i> , <i>J. Lipid Res.</i> , 32:197-204 (1991).	
	EJ	KELAREV, V.I., <i>et al.</i> , <i>Khim. Geterotsikl. Soedin.</i> , no. 5, pages 667-673 (1995). Provided as <i>Chem. Abstracts</i> , AN 124:146082, XP002115604.	
	EK	KELAREV, V.I., <i>et al.</i> , <i>Khim. Geterotsikl. Soedin.</i> , no. 4, pages 514-517 (1995). Provided as <i>Chem. Abstracts</i> AN 124(1):8690 (January 1, 1996) XP002115603 and XP002115596.	
	EL	KOCH, A.E., <i>et al.</i> , "Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues", <i>Lab. Invest.</i> , 64(3):313-320 (1991).	
	EM	LANKIN, V.Z., <i>et al.</i> , <i>Dokl. Akad. Nauk.</i> , 351(4):554-557 (1996), <i>Chem. Abstracts</i> , AN 127(6):75973u (1997), XP002115597.	
	EN	MAMEDOV, Ch.I., <i>et al.</i> , <i>Mater. Nauchn. Konf. Aspir. Akad. Nauk Az. SSR</i> , 1:127-131 (1980), <i>Chem. Abstracts</i> , AN 94:30290c (1981), XP002115600	
	EO	MAO., S.J., <i>et al.</i> , "Antioxidant Activity of Probucol and Its Analogues in Hypercholesterolemic watanabe Rabbits," <i>Journal of Medicinal Chemistry</i> , 34(1):298-302 (January 1991).	
	EP	MAO, S.J., <i>et al.</i> , "Attenuation of Atherosclerosis in a Modified Strain of Hypercholesterolemic Watanabe Rabbits with Use of a Probucol Analogue (MDL29,311) That Does Not Lower serum Cholesterol," <i>Arteriosclerosis and Thrombosis</i> , 11(5):1266-1275 (September-October 1991)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

*Complete if Known*

Application Number

10/647,766

Filing Date

August 25, 2003

First Named Inventor

Somers

Group Art Unit

Unassigned

Examiner Name

Unassigned

Sheet

6

of

7

Attorney Docket Number

04676.105082 ATH 109 CON 6

3563879 2.DOC

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	FA	MEDVEDEV, A.I., <i>et al.</i> , <i>Tezisy Dokl. Nauchn. Sess. Khim. Tekhnol. Org. Soedin. Sery Sernistykh Neftei</i> , 13 <sup>th</sup> , pages 123-124 (1974), <i>Chem. Abstracts</i> , AN 86(1):5066m (p. 437, 01-03-1977). XP002115601, XP00215594.	
	FB	MILLER, G.J., "High density lipoproteins and atherosclerosis", <i>Ann. Rev. Med.</i> , 31:97-108 (1980).	
	FC	MORALES-DUCRET, J., <i>et al.</i> , "α4/β1 integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes", <i>J. Immunol.</i> , 149(4):1424-1431 (August 15, 1992).	
	FD	NEUWORTH, M.B., "Synthesis and hypocholesterolemic activity of alkylidenedithio bisphenols," <i>J. Med. Chem.</i> , 13(4) 722-725 (1970), <i>Chem. Abstracts</i> AN 73:445047 (1970), XP002124423.	
	FE	OHKAWARA, Y., <i>et al.</i> , "In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: <i>In vivo</i> evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration", <i>Am. J. Respir. Cell. Mol. Biol.</i> , 12:4-12 (1995).	
	FF	OROSZ, C.G., <i>et al.</i> , "Role of the endothelial adhesion molecule VCAM in murine cardiac allograft rejection", <i>Immunol. Lett.</i> , 32:7-12 (1992).	
	FG	PARTHASARATHY, S., <i>et al.</i> , "Probucol inhibits oxidative modification of low density lipoprotein", <i>J. Clin. Invest.</i> , 77:641-644 (1986).	
	FH	PASTOR, S.D., <i>et al.</i> , <i>Phosphorus and Sulfur</i> , 37(3-4):117-123 (1988), <i>Chemical Abstracts</i> , AN 110(23):212254a (June 5, 1989), XP0021156682.	
	FI	PATTON, J.G., <i>et al.</i> , "Monoclonal antibodies to human plasma low-density lipoproteins. II. Evaluation for use in radioimmunoassay for apolipoprotein B in patients with coronary artery disease", <i>Clin. Chem.</i> , 29(11):1898-1903 (1983).	
	FJ	PILEWSKI, J.M., <i>et al.</i> , "Cell adhesion molecules in asthma: homing, activation, and airway remodeling", <i>J. Respir. Cell. Mol. Biol.</i> , 12:1-3 (1995).	
	FK	RABB, H.A., <i>et al.</i> , "The role of the leukocyte adhesion molecules VLA-4, LFA-1 and Mac-1 in allergic airway responses in the rat", <i>Am. J. Respir. Crit. Care Med.</i> , 149:1186-1191 (1994).	
	FL	RAMASAMY, S., <i>et al.</i> , "Modulation of Expression of Endothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, a Phenolic Antioxidant in Cultured Endothelial Cells," <i>Molecular Pharmacology</i> , 56(1):116-123 (April 5, 1999).	
	FM	RINNINGER, <i>et al.</i> , "Probucol enhances selective uptake of HDL-associated cholestryll esters in vitro by a scavenger receptor B-I-dependent mechanism", <i>Atherosclerosis Thromb. Vasc. Biol.</i> , 19:1325-1332 (1999). XP-008001008.	
	FN	ROBERTS, C.P., <i>et al.</i> , "Regulation of Monocyte Macrophage Differentiation by Antiglucocorticoids and Antioxidants," <i>American Journal of Obstetrics and Gynecology</i> , 179(2): 354-62 (August 1998).	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/647,766
				Filing Date	August 25, 2003
				First Named Inventor	Somers
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	7	of	7	Attorney Docket Number	04676.105082 ATH 109 CON 6

3563879\_2.DOC

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>		
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. <sup>2</sup>
	GA	SAWAYAMA, Y., <i>et al.</i> , "Effects of Probucol and Pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia", <i>Journal of the American College of Cardiology</i> , 39(4):610-616 (2002) <sup>3</sup>
	GB	STEINBERG, D., <i>et al.</i> , "Modifications of low-density lipoprotein that increase its atherogenicity", <i>N. Eng. J. Med.</i> , 220(14):915-924 (1989). <sup>4</sup>
	GC	TOMICH <i>et al.</i> , <i>Chemical Abstracts</i> , AN 127(6):75971s (1997). <sup>5</sup>
	GD	WAGNER, Jr., <i>et al.</i> , <i>Chemical Abstracts</i> , AN 82:86189w (1975). <sup>6</sup>
	GE	YANG, X.-D., <i>et al.</i> , "Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 90:10494-10498 (1993). <sup>7</sup>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.